Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Escudier B, Grünwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E.

Clin Cancer Res. 2014 Jun 1;20(11):3012-22. doi: 10.1158/1078-0432.CCR-13-3006. Epub 2014 Apr 1.

2.

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.

Guo J, Huang Y, Zhang X, Zhou F, Sun Y, Qin S, Ye Z, Wang H, Jappe A, Straub P, Pirotta N, Gogov S.

BMC Cancer. 2013 Mar 21;13:136. doi: 10.1186/1471-2407-13-136.

3.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

PMID:
21803569
4.

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.

Jannuzzo MG, Di Salle E, Spinelli R, Pirotta N, Buchan P, Bello A.

Breast Cancer Res Treat. 2009 Feb;113(3):491-9. doi: 10.1007/s10549-008-9949-9. Epub 2008 Mar 11.

PMID:
18330698
5.

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.

6.

Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB.

Clin Lung Cancer. 2001 May;2 Suppl 2:S26-33.

PMID:
14725727
7.

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB.

J Clin Oncol. 2001 Feb 15;19(4):1078-87.

PMID:
11181672
8.

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL.

Oncologist. 2001;6(1):81-91.

9.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL.

N Engl J Med. 2000 Sep 28;343(13):905-14.

10.

Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients.

Dautzenberg B, Castellani P, Pellegrin JL, Vittecoq D, Truffot-Pernot C, Pirotta N, Sassella D.

Antimicrob Agents Chemother. 1996 Jul;40(7):1722-5.

11.

Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS.

Dautzenberg B, Olliaro P, Ruf B, Esposito R, Opravil M, Hoy JF, Rozenbaum W, Carosi GP, Micoud M, L'Age M, Pirotta N, Sassella D.

Clin Infect Dis. 1996 Apr;22(4):705-8.

PMID:
8729209
12.

Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA).

Cataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E.

Circulation. 1993 Nov;88(5 Pt 2):II93-8.

PMID:
8222202
13.

"Within patient"-dependent outcomes in graft occlusion after coronary artery bypass. SINBA Group.

Marubini E, Braga M, Leite ML, Petroccione A, Pirotta N.

Control Clin Trials. 1993 Aug;14(4):296-307.

PMID:
8365194
14.

Determinants of caesarean section rates in Italy.

Parazzini F, Pirotta N, La Vecchia C, Fedele L.

Br J Obstet Gynaecol. 1992 Mar;99(3):203-6.

PMID:
1606117
15.

Determinants of perinatal and infant mortality in Italy.

Parazzini F, Pirotta N, La Vecchia C, Bocciolone L, Fedele L.

Rev Epidemiol Sante Publique. 1992;40(1):15-24.

PMID:
1604024
16.

[Determinants of the frequency of cesarean section in Italy, 1980-1983].

Buttino I, Tozzi L, Bocciolone L, Pirotta N, Parazzini F.

Ann Ostet Ginecol Med Perinat. 1990 Jul-Aug;111(4):245-56. Italian.

PMID:
2088156
17.

[Determinants of perinatal and infant mortality in Italy 1980-1983].

Parazzini F, Pirotta N, La Vecchia C, Fedele L.

Ann Ostet Ginecol Med Perinat. 1990 Jan-Apr;111(1-2):9-146. Italian.

PMID:
2256605

Supplemental Content

Loading ...
Support Center